GRK5 and cystic fibrosis: Our results identify GRK5 as a putative novel therapeutic target for CF, which can be inhibited with the selective inhibitors 9g or 9j to maximize p.Phe508del-CFTR rescue by current approved corrector drugs, including the highly effective modulator therapy combining ETI.